Skip to Main Content
Important Announcement: The New Library System and updated E-resource login process are Here!. As part of
OhioLINK, Ohio's academic library consortium, the NEOMED Library is updating its 30-year-old shared systems. The new system allows researchers to "discover" print and electronic resources with a single search. Click
here to start using the new system.
Additionally, we have also changed the way that you all will login for off-campus access to the electronic resources provided by the NEOMED Library. All NEOMED students, faculty, clinical faculty, staff, and retirees, will click on the "Login using your NEOMED Network credentials" link on the login page. From there, you will be routed through NEOMED's network login process using the same login credentials that you use for logging into your email, Sharepoint, and other essential NEOMED networked resources.
Please be patient with us as we get everything situated for your use and contact us with any questions at 330-325-6600 or e-mail
library@neomed.edu for help.
Breast cancer
- Comparing trastuzumab to bevacizumab for the treatment of breast cancer
- Zoledronate versus ibandronate for the treatment of breast cancer
- Anastrozole versus tamoxifen for the treatment of breast cancer
- Letrozole versus tamoxifen for treating breast cancer
- Letrozole versus anastrozole for treating breast cancer
Accelerated approval for new cancer drugs
- Vemurafenib (formerly PLX4032) for treating metastatic melanoma. Find one randomized control trial comparing this drug to another drug. For your second article, find an article testing PLX4032 on cancer cell lines. Choose a review article of your choice.
- Crizotinib for treating non-small cell lung cancer. See H. McEwen about the choosing your articles.
Melanoma
- Ipilimumab and sargramostim compared to ipilimumab for treating metastatic melanoma
- Nivolumab vs ipilimumab for treating melanoma
- Nivolumab vs Ipilimumab vs Nivolumab and Ipilimumab for treating advanced melanoma
- Vemurafenib vs dabrafenib vs trametinib for treating metastatic melanoma